{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:12Z","timestamp":1790108772873,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["APP2002565"],"award-info":[{"award-number":["APP2002565"]}]},{"name":"Australian National Health and Medical Research Council","award":["APP1149976"],"award-info":[{"award-number":["APP1149976"]}]},{"DOI":"10.13039\/100009781","name":"Australian Centre for HIV and Hepatitis Virology Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007811","name":"Sydney Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007811","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) infection can now be cured with well-tolerated direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the emergence of resistance-associated substitutions (RASs) that reduce the efficacy of antiviral drugs, but real-world studies assessing the clinical impact of RASs are limited. Here, an analysis of the impact of RASs on retreatment outcomes for different salvage regimens in patients nationally who failed first-line DAA therapy is reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We collected data from 363 Australian patients who failed first-line DAA therapy, including: age, sex, fibrosis stage, HCV genotype, NS3\/NS5A\/NS5B RASs, details of failed first-line regimen, subsequent salvage regimens, and treatment outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 240 patients who were initially retreated as per protocol, 210 (87.5%) achieved sustained virologic response (SVR) and 30 (12.5%) relapsed or did not respond. The SVR rate for salvage regimens that included sofosbuvir\/velpatasvir\/voxilaprevir was 94.3% (n = 140), sofosbuvir\/velpatasvir 75.0% (n = 52), elbasvir\/grazoprevir 81.6% (n = 38), and glecaprevir\/pibrentasvir 84.6% (n = 13). NS5A RASs were present in 71.0% (n = 210) of patients who achieved SVR and in 66.7% (n = 30) of patients who subsequently relapsed. NS3 RASs were detected in 20 patients (20%) in the SVR group and 1 patient in the relapse group. NS5B RASs were observed in only 3 patients. Cirrhosis was a predictor of relapse after retreatment, as was previous treatment with sofosbuvir\/velpatasvir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In our cohort, the SVR rate for sofosbuvir\/velpatasvir\/voxilaprevir was higher than with other salvage regimens. The presence of NS5A, NS5B, or NS3 RASs did not appear to negatively influence retreatment outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae155","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T10:47:00Z","timestamp":1710758820000},"source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia"],"prefix":"10.1093","volume":"11","author":[{"given":"Dao Sen","family":"Wang","sequence":"first","affiliation":[{"name":"Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Phu","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"McKee","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I","family":"Strasser","sequence":"additional","affiliation":[{"name":"AW Morrow Gastroenterology and Liver Centre, The University of Sydney and Royal Prince Alfred Hospital , Camperdown, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Sheils","sequence":"additional","affiliation":[{"name":"AW Morrow Gastroenterology and Liver Centre, The University of Sydney and Royal Prince Alfred Hospital , Camperdown, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weltman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nepean Hospital , Kingswood, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Sellar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nepean Hospital , Kingswood, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Newcastle and John Hunter Hospital , Newcastle, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Newcastle and John Hunter Hospital , Newcastle, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Braund","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gold Coast University Hospital , Southport, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey C","family":"Farrell","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Australian National University and The Canberra Hospital , Canberra, ACT , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blunn","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Australian National University and The Canberra Hospital , Canberra, ACT , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Harding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Lyell McEwin Hospital , Elizabeth Vale, SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Ralton","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Lyell McEwin Hospital , Elizabeth Vale, SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Flinders Medical Centreand Flinders University , Adelaide, SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A","family":"Davison","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University of New South Wales and Liverpool Hospital , Liverpool, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Adelaide Hospital , Adelaide, SA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnie","family":"Wood","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Royal Brisbane and Women's Hospital , Brisbane, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krispin","family":"Hajkowicz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Royal Brisbane and Women's Hospital , Brisbane, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Skolen","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Royal Brisbane and Women's Hospital , Brisbane, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Davies","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research and Royal Darwin Hospital , Darwin, NT , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Tate-Baker","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research and Royal Darwin Hospital , Darwin, NT , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Doyle","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal Perth Hospital , Perth, WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda","family":"Tuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal Perth Hospital , Perth, WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hazeldine","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fiona Stanley Hospital , Murdoch, WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Fiona Stanley Hospital , Murdoch, WA , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Edmiston","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, School of Medicine, Western Sydney University , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Zohrab","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, School of Medicine, Western Sydney University , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pratt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shoalhaven Hospital , Nowra, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shoalhaven Hospital , Nowra, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Zekry","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, St George Hospital , Kogarah, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlie","family":"Stephens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, St George Hospital , Kogarah, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Clark","sequence":"additional","affiliation":[{"name":"Rockhampton Blood Borne Virus & Sexual Health Service and School of Medicine, University of Brisbane , Brisbane, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melany","family":"Day","sequence":"additional","affiliation":[{"name":"Rockhampton Blood Borne Virus & Sexual Health Service and School of Medicine, University of Brisbane , Brisbane, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal North Shore Hospital , St Leonards, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hami","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal North Shore Hospital , St Leonards, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Royal Hobart Hospital , Hobart, TAS , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"McGarity","sequence":"additional","affiliation":[{"name":"Bathurst Liver Clinic , Bathurst, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Menzies","sequence":"additional","affiliation":[{"name":"Bathurst Liver Clinic , Bathurst, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Russell","sequence":"additional","affiliation":[{"name":"Cairns Sexual Health Service and James Cook University Cairns , St Cairns City, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Drug Health, Western Sydney Local Health District , Westmead, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boyd","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cairns Hospital , Cairns, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen","family":"Kok","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital , Westmead, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-3485","authenticated-orcid":false,"given":"Mark W","family":"Douglas","sequence":"additional","affiliation":[{"name":"Storr Liver Centre, The Westmead Institute for Medical Research, The University of Sydney and Westmead Hospital , Sydney, NSW , Australia"},{"name":"Centre for Infectious Diseases and Microbiology, Sydney Infectious Diseases Institute, The University of Sydney at Westmead Hospital , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"2024042220534023600_ofae155-B1","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2013the arc of a medical triumph","volume":"370","author":"Chung","year":"2014","journal-title":"N Engl J Med"},{"key":"2024042220534023600_ofae155-B2","volume-title":"Monitoring hepatitis C treatment uptake in Australia, issue 13","author":"The Kirby Institute","year":"2023"},{"key":"2024042220534023600_ofae155-B3","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021\u2014towards ending viral hepatitis","author":"WHO","year":"2016"},{"key":"2024042220534023600_ofae155-B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"2024042220534023600_ofae155-B5","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"O005: retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24 weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B6","doi-asserted-by":"crossref","first-page":"41719","DOI":"10.1038\/srep41719","article-title":"Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment","volume":"7","author":"Eltahla","year":"2017","journal-title":"Sci Rep"},{"key":"2024042220534023600_ofae155-B7","first-page":"541","article-title":"Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges","volume":"31","author":"Shahnazarian","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2024042220534023600_ofae155-B8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"2024042220534023600_ofae155-B10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/hep4.1496","article-title":"Impact of an open access nationwide treatment model on hepatitis C virus antiviral drug resistance","volume":"4","author":"Douglas","year":"2020","journal-title":"Hepatol Commun"},{"key":"2024042220534023600_ofae155-B11","doi-asserted-by":"crossref","first-page":"100462","DOI":"10.1016\/j.jhepr.2022.100462","article-title":"Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals","volume":"4","author":"Howe","year":"2022","journal-title":"JHEP Rep"},{"key":"2024042220534023600_ofae155-B12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3851\/IMP3317","article-title":"Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales","volume":"24","author":"Ong","year":"2019","journal-title":"Antivir Ther"},{"key":"2024042220534023600_ofae155-B13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2022.08.016","article-title":"Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure","volume":"78","author":"Dietz","year":"2023","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"2024042220534023600_ofae155-B15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/j.gastro.2014.05.010","article-title":"Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man","volume":"147","author":"Franco","year":"2014","journal-title":"Gastroenterology"},{"key":"2024042220534023600_ofae155-B16","first-page":"1271","article-title":"Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men","volume":"63","author":"Abravanel","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024042220534023600_ofae155-B17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B18","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"2024042220534023600_ofae155-B19","author":"Bourli\u00e8re"},{"key":"2024042220534023600_ofae155-B20","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"EASL","year":"2020","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024042220534023600_ofae155-B22","volume-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018)","author":"Hepatitis C Virus Infection Consensus Statement Working Group","year":"2018"},{"key":"2024042220534023600_ofae155-B23","volume-title":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2016","author":"Hepatitis C Virus Infection Consensus Statement Working Group","year":"2016"},{"key":"2024042220534023600_ofae155-B24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"2024042220534023600_ofae155-B25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2019.09.011","article-title":"Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia","volume":"120","author":"Papaluca","year":"2019","journal-title":"J Clin Virol"},{"key":"2024042220534023600_ofae155-B26","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/jvh.13549","article-title":"Real world SOF\/VEL\/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy","volume":"28","author":"Smith","year":"2021","journal-title":"J Viral Hepat"},{"key":"2024042220534023600_ofae155-B27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"J Viral Hepat"},{"key":"2024042220534023600_ofae155-B29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cix916","article-title":"Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE study","volume":"66","author":"de Ledinghen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024042220534023600_ofae155-B31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)\u2014NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B32","doi-asserted-by":"crossref","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics","volume":"73","author":"Papaluca","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024042220534023600_ofae155-B33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12072-022-10475-9","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan","volume":"17","author":"Liu","year":"2023","journal-title":"Hepatol Int"},{"key":"2024042220534023600_ofae155-B34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"2024042220534023600_ofae155-B36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","article-title":"Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy","volume":"74","author":"Dietz","year":"2021","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2021.02.024","article-title":"Glecaprevir\/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings","volume":"75","author":"Martin","year":"2021","journal-title":"J Hepatol"},{"key":"2024042220534023600_ofae155-B38","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/jam.15754","article-title":"Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients","volume":"133","author":"Younas","year":"2022","journal-title":"J Appl Microbiol"},{"key":"2024042220534023600_ofae155-B39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/HEP.0000000000000353","article-title":"Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system","volume":"78","author":"Fernandez-Antunez","year":"2023","journal-title":"Hepatology"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae155\/57001603\/ofae155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/4\/ofae155\/57303385\/ofae155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/4\/ofae155\/57303385\/ofae155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T20:54:09Z","timestamp":1713819249000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae155\/7630796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae155","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,18]]},"article-number":"ofae155"}}